|
|
|
Small alterations in a gene required for responding to chemotherapy can result in drug-resistant ovarian cancer, Alan D'Andrea and his colleagues report in the May issue of Nature Medicine.
In the United States alone, there are approximately 23,000 new cases of ovarian cancer diagnosed per year, and more than 15,000 women die from the disease. Ovarian cancer cells are initially sensitive to chemotherapeutic drugs such as cisplatin but, by an unknown mechanism, become resistant to the drugs over time. Understanding how the cells become resistant could lead to new drugs to treat the cancer, the researchers say. The researchers examined the Fanconi anemia-BRCA pathway, which regulates sensitivity to cisplatin, in ovarian tumor cells. They found that the pathway is disrupted in some ovarian tumors and identified an early event -- the removal of methyl groups from a critical gene in the pathway -- that causes cisplatin resistance. Author contact: Alan D. D'Andrea
Division of Pediatric Oncology
Dana-Farber Cancer Institute
Boston, MA
USA
Tel: +1 617 632 2080
E-mail: alan_dandrea@dfci.harvard.edu Also available online. (C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|